@Article{info:doi/10.2196/20829,
author="Ebenfeld, Lara
and Lehr, Dirk
and Ebert, David Daniel
and Kleine Stegemann, Stefan
and Riper, Heleen
and Funk, Burkhardt
and Berking, Matthias",
title="Evaluating a Hybrid Web-Based Training Program for Panic Disorder and Agoraphobia: Randomized Controlled Trial",
journal="J Med Internet Res",
year="2021",
month="Mar",
day="4",
volume="23",
number="3",
pages="e20829",
keywords="panic disorder; agoraphobia; treatment; internet; mobile phone; randomized controlled trial",
abstract="Background: Previous studies provide evidence for the effectiveness of web-based interventions for panic disorder with and without agoraphobia. Smartphone-based technologies hold significant potential for further enhancing the accessibility and efficacy of such interventions. Objective: This randomized controlled trial aims to evaluate the efficacy of a guided, hybrid web-based training program based on cognitive behavioral therapy for adults with symptoms of panic disorder. Methods: Participants (N=92) with total scores in the Panic and Agoraphobia Scale ranging from 9 to 28 were recruited from the general population and allocated either to a hybrid intervention (GET.ON Panic) or to a wait-list control group. The primary outcome was the reduction in panic symptoms, as self-assessed using a web-based version of the Panic and Agoraphobia Scale. Results: Analysis of covariance-based intention-to-treat analyses revealed a significantly stronger decrease in panic symptoms posttreatment (F=9.77; P=.002; Cohen d=0.66; 95{\%} CI 0.24-1.08) in the intervention group than in the wait-list control group. Comparisons between groups of the follow-up measures at 3 and 6 months yielded even stronger effects (3-month follow-up: F=17.40, P<.001, Cohen d=0.89, 95{\%} CI 0.46-1.31; 6-month follow-up: F=14.63, P<.001, Cohen d=0.81, 95{\%} CI 0.38-1.24). Conclusions: Hybrid web-based training programs may help reduce the symptoms of panic disorder and hence play an important role in improving health care for patients with this debilitating disorder. Trial Registration: German Clinical Trial Register DRKS00005223; https://tinyurl.com/f4zt5ran International Registered Report Identifier (IRRID): RR2-10.1186/1745-6215-15-427 ",
issn="1438-8871",
doi="10.2196/20829",
url="https://www.jmir.org/2021/3/e20829",
url="https://doi.org/10.2196/20829",
url="http://www.ncbi.nlm.nih.gov/pubmed/33661121"
}